RESULTS:
Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response.

CONCLUSION:
A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.

AD

Department of Medicine, University of Washington Medical Center 98155.